Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Kelly C. Goldsmith et al.|Clinical Cancer Research|2018Cited by 88
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyRochelle Bagatell, Lisa Hang, Julie R. Park et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 47
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Yimei Li et al.|Journal of Clinical Oncology|2022Cited by 42
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E. Norris, Rochelle Bagatell, Suzanne Shusterman et al.|Pediatric Blood & Cancer|2014Cited by 34